Welcome to LookChem.com Sign In|Join Free
  • or
Acetic acid, 2,2'-[[4-[7-(carboxymethoxy)-5-hydroxy-4-oxo-4H-1-benzopyran-2-yl]-1, 2-phenylene]bis(oxy)]bis- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

501445-13-2

Post Buying Request

501445-13-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

501445-13-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 501445-13-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,1,4,4 and 5 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 501445-13:
(8*5)+(7*0)+(6*1)+(5*4)+(4*4)+(3*5)+(2*1)+(1*3)=102
102 % 10 = 2
So 501445-13-2 is a valid CAS Registry Number.

501445-13-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-Hydroxy-3',4',7-tricarboxymethyloxyflavone

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:501445-13-2 SDS

501445-13-2Upstream product

501445-13-2Downstream Products

501445-13-2Relevant academic research and scientific papers

Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto

-

, (2008/06/13)

3-Deoxyflavonoid compounds and methods for inhibiting T-cell activity and treating diseases and disorders (e.g., autoimmune disorders, inflammatory disorders, diabetes, ALS, MS, rheumatoid arthritis, etc.). In some cases the efficacy and/or duration of action of luteolin and/or other 3-deoxyflavonoid compounds may be increased by administering such compounds along with Rutin, a Rutin congener and/or a Rutin derivative. Also, in some cases, first pass metabolism of luteolin or other 3-deoxyflavonoids may be avoided by administering such compounds by parenteral routes (e.g., routes wherein absorption occurs at sites other than the stomach or intestinal mucosa, such as sublingual, buccal, intranasal, injection, etc.).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 501445-13-2